全文获取类型
收费全文 | 3848篇 |
免费 | 323篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 73篇 |
儿科学 | 125篇 |
妇产科学 | 101篇 |
基础医学 | 481篇 |
口腔科学 | 94篇 |
临床医学 | 570篇 |
内科学 | 945篇 |
皮肤病学 | 121篇 |
神经病学 | 234篇 |
特种医学 | 262篇 |
外科学 | 347篇 |
综合类 | 116篇 |
一般理论 | 1篇 |
预防医学 | 333篇 |
眼科学 | 20篇 |
药学 | 164篇 |
中国医学 | 6篇 |
肿瘤学 | 215篇 |
出版年
2023年 | 15篇 |
2022年 | 15篇 |
2021年 | 51篇 |
2020年 | 27篇 |
2019年 | 64篇 |
2018年 | 75篇 |
2017年 | 46篇 |
2016年 | 47篇 |
2015年 | 65篇 |
2014年 | 77篇 |
2013年 | 138篇 |
2012年 | 154篇 |
2011年 | 172篇 |
2010年 | 120篇 |
2009年 | 123篇 |
2008年 | 141篇 |
2007年 | 160篇 |
2006年 | 158篇 |
2005年 | 194篇 |
2004年 | 157篇 |
2003年 | 140篇 |
2002年 | 153篇 |
2001年 | 155篇 |
2000年 | 132篇 |
1999年 | 139篇 |
1998年 | 90篇 |
1997年 | 92篇 |
1996年 | 83篇 |
1995年 | 64篇 |
1994年 | 80篇 |
1993年 | 68篇 |
1992年 | 120篇 |
1991年 | 65篇 |
1990年 | 69篇 |
1989年 | 87篇 |
1988年 | 103篇 |
1987年 | 62篇 |
1986年 | 65篇 |
1985年 | 85篇 |
1984年 | 46篇 |
1983年 | 32篇 |
1982年 | 27篇 |
1981年 | 26篇 |
1980年 | 30篇 |
1979年 | 32篇 |
1978年 | 24篇 |
1977年 | 16篇 |
1976年 | 23篇 |
1975年 | 17篇 |
1968年 | 15篇 |
排序方式: 共有4208条查询结果,搜索用时 15 毫秒
991.
Idiotype as a tumor-specific marker in childhood B cell acute lymphoblastic leukemia 总被引:1,自引:0,他引:1
Carroll WL; Link MP; Cleary ML; Bologna S; Carswell C; Amylon MD; Smith SD; Levy R 《Blood》1988,71(4):1068-1073
Immunoglobulin (Ig) or idiotype (Id) is a tumor-specific target in those B cell malignancies that express this molecule on their surface. We explored the biology of B cell acute lymphoblastic leukemia (B cell ALL) using Id as a tumor marker. In this report we describe the development of anti-Id monoclonal antibodies (MAB) for two children with B cell ALL. These reagents were used retrospectively to study tumor kinetics and to detect residual disease after chemotherapy. In both cases serum Id values were strikingly high at diagnosis (1.2 mg/mL and 10.8 mg/mL), suggesting that the tumor cells were relatively mature B cells capable of significant antibody production. In both patients the serum Id levels fell with the institution of therapy and confirmed that the patients were in remission. Increasing serum Id predicted relapse four months before conventional methods in patient 1, and Id proved to be a more sensitive measure of tumor burden than Southern blot analysis of rearranged Ig genes in bone marrow samples. Surprisingly, low levels of Id were redetected in the second patient just before completing therapy and have persisted for over a year despite the absence of clinical evidence of recurrent disease. Thus, serum Id levels reflect tumor burden during initial therapy but may not necessarily predict tumor progression after a complete clinical remission. 相似文献
992.
Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia 总被引:1,自引:5,他引:1
Gajjar A; Ribeiro R; Hancock ML; Rivera GK; Mahmoud H; Sandlund JT; Crist WM; Pui CH 《Blood》1995,86(4):1292-1295
Early response to therapy, typically assessed by bone marrow status, is predictive of outcome in childhood acute lymphoblastic leukemia (ALL). Less is known about the significance of early clearance of blast cells in peripheral blood. We reviewed medical records of all patients with ALL enrolled on St Jude Total Therapy Study XI (February 1984 to September 1988) to determine the presence of blast cells in peripheral blood at diagnosis and after 1 week of intensive induction therapy. Of the 358 patients, 59 lacked evidence of circulating blast cells at diagnosis, and data were unavailable for 2 patients. The prognostic significance of persistent circulating blast cells in the remaining 297 patients was assessed in a multivariate analysis that included known adverse prognostic factors. Persistent circulating leukemic blasts were present at day 8 in 41 patients (14%). Compared with the "blast- negative" group, these patients had a significantly higher frequency of several adverse clinical features (leukocyte count > 50 x 10(9)/L, mediastinal mass, central nervous system leukemia, T-cell phenotype, lack of CD10 expression, and L2 morphology) and a significantly poorer 5-year event-free survival (34% +/- 8% [SE] v 77% +/- 3%, P < .01). By multivariate analysis, blast cell persistence at week 1 was the most significant adverse feature in the overall cohort (relative risk, 2.9; 95% confidence interval, 1.8 to 4.8) and in an analysis limited to B- lineage cases (relative risk, 3.6; 95% confidence interval, 1.9 to 7.1). Patients identified by this simple, noninvasive measure may benefit from early modification of therapy. 相似文献
993.
Characterization of a suppressor T-cell chronic lymphocytic leukemia with ADCC but not NK activity 总被引:6,自引:0,他引:6
A patient with T-cell chronic lymphocytic leukemia (T-CLL) is reported whose cells demonstrate in vitro suppression of normal lymphocyte mitogen stimulation. The patient, who remains in Rai's clinical stage 0 on no therapy after more than 24 mo of observation, has shown a less aggressive clinical course than is usually attributed to T-CLL. His peripheral blood lymphocytes (PBL) were characterized by functional assays as well as surface markers. Over 90% of the patient's PBL formed rosettes with sheep erythrocytes and were lysed by two T-cell-specific antisera plus complement, while less than 1% bore surface immunoglobulins, and only 3% had complement receptors. In addition, 45% of the PBL demonstrated Ia-like antigens, more than 50% expressed a receptor for the Fc portion of IgG(T gamma), and most of the sheep erythrocyte rosettes were inhibited by theophylline. The patient's cells failed to respond to several mitogens and they caused marked suppression of lymphoproliferative responses to normal PBL to phytohemagglutinin (PHA) and concanavalin A (Con-A). The patient's lymphocytes also exhibited antibody-dependent cytotoxic activity (ADCC) against antibody-coated nucleated target cells, but lacked demonstrable natural killer (NK) activity. This patient's T-CLL cells appear to represent the clonal expansion of a subset of T cells with a previously undescribed pattern of suppressor and cytotoxic activities. 相似文献
994.
Down syndrome (DS) children with acute myeloid leukemia (AML) have significantly higher event-free survival (EFS) rates compared with non- DS children when treated with protocols containing 1-beta-D- arabinofuranosylcytosine (ara-C). Sensitivity and metabolism of ara-C was examined in myeloblasts from DS and non-DS patients with AML, DS infants with the transient myeloproliferative disorder, and Epstein- Barr Virus (EBV) transformed lymphoblastoid cell lines with and without trisomy 21. DS myeloblasts were approximately 10-fold more sensitive to ara-C (measured by the 3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) colorimetric sensitivity assay), compared with non-DS myeloblasts, following exposure to ara-C for 72 hours. Mean levels of l-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP) were significantly higher in DS myeloblasts compared with non-DS myeloblasts after incubation with 5 micromol/L ara-C (621.4 v 228.4 pmol/mg protein). DS cell lines also generated higher levels of ara-CTP compared with cell lines with diploid chromosome numbers (66.5 v 13.6 pmol/mg protein and 137.6 v 41.7 pmol/mg protein at 1 and 5 micromol/L ara-C, respectively). Elevated ara-CTP levels in the DS cells were accompanied by slightly lower levels of endogenous deoxycytidine triphosphate (dCTP) pools, slightly greater extent of ara-C incorporation into DNA, and increased relative numbers of double strand DNA strand breaks. There were no significant differences in the cell cycle distributions of DS and non-DS cells. These in vitro studies support our hypothesis that enhanced metabolism of ara-C in DS cells may be a contributing factor to the superior survival rate of DS children with AML and is possibly based on a gene dosage effect of genes localized to chromosome 21 including cystathionine-beta-synthase. Further study of the mechanisms (ie, alterations in dCTP pools and DNA methylation) involved may lead to improvements in the treatment of all AML patients. 相似文献
995.
996.
Elisabetta Bianchi Joseph G. Joyce Michael D. Miller Adam C. Finnefrock Xiaoping Liang Marco Finotto Paolo Ingallinella Philip McKenna Michael Citron Elizabeth Ottinger Robert W. Hepler Renee Hrin Deborah Nahas Chengwei Wu David Montefiori John W. Shiver Antonello Pessi Peter S. Kim 《Proceedings of the National Academy of Sciences of the United States of America》2010,107(23):10655-10660
Eliciting a broadly neutralizing polyclonal antibody response against HIV-1 remains a major challenge. One approach to vaccine development is prevention of HIV-1 entry into cells by blocking the fusion of viral and cell membranes. More specifically, our goal is to elicit neutralizing antibodies that target a transient viral entry intermediate (the prehairpin intermediate) formed by the HIV-1 gp41 protein. Because this intermediate is transient, a stable mimetic is required to elicit an immune response. Previously, a series of engineered peptides was used to select a mAb (denoted D5) that binds to the surface of the gp41 prehairpin intermediate, as demonstrated by x-ray crystallographic studies. D5 inhibits the replication of HIV-1 clinical isolates, providing proof-of-principle for this vaccine approach. Here, we describe a series of peptide mimetics of the gp41 prehairpin intermediate designed to permit a systematic analysis of the immune response generated in animals. To improve the chances of detecting weak neutralizing polyclonal responses, two strategies were employed in the initial screening: use of a neutralization-hypersensitive virus and concentration of the IgG fraction from immunized animal sera. This allowed incremental improvements through iterative cycles of design, which led to vaccine candidates capable of generating a polyclonal antibody response, detectable in unfractionated sera, that neutralize tier 1 HIV-1 and simian HIV primary isolates in vitro. Our findings serve as a starting point for the design of more potent immunogens to elicit a broadly neutralizing response against the gp41 prehairpin intermediate. 相似文献
997.
998.
999.
K. Rajender Reddy Mitchell L. Shiffman Maribel Rodriguez–Torres Hugo Cheinquer Djamal Abdurakhmanov Igor Bakulin Viacheslav Morozov Giovanni Faria Silva Natalia Geyvandova Carol Stanciu Michael Rabbia Michael McKenna James A. Thommes Stephen A. Harrison PROGRESS Study Investigators 《Gastroenterology》2010,139(6):1972-1983
1000.
ML Von Linstow V Rosenfeldt AM Lebech M Storgaard T Hornstrup TL Katzenstein G Pedersen T Herlin NH Valerius N Weis 《HIV medicine》2010,11(7):448-456